ArticleJournal of periodontology2026
Bone regeneration using aged donor cells and visible light-curable hydrogel: An in vitro and in vivo evaluation.
Article in Journal of periodontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundTransplantation therapy combining scaffolds and cells can be used for extensive bone regeneration (e.g., to manage severe alveolar bone defects). Gelatin methacryloyl (GelMA) may be a suitable scaffold for cell transplantation. We developed a novel GelMA that polymerizes under visible light, using riboflavin as a photoinitiator (GelMA-RF). Here we investigated the efficacy of bone-regenerative therapy combining GelMA-RF and immature osteoblasts in rats.
methodsRat alveolar bone immature osteoblasts (RAOBs) from 70-week-old rats were encapsulated in GelMA-RF (aged RAOBs + GelMA-RF) and transplanted into palatal (control, RAOBs alone, and RAOBs + GelMA-RF groups; n = 8, respectively) or femoral (control, GelMA-RF alone, RAOBs alone, and RAOBs + GelMA-RF groups; n = 8, respectively) bone defects. Macroscopic assessment, micro-computed tomography, and histological analyses were performed, and mineralization (aged and young RAOBs with or without osteogenic differentiation (OD) groups; n = 8, respectively) and the calcium/phosphorus ratio (aged and young RAOBs in OD+ or OD- groups; n = 8, respectively) for RAOBs under 3D-culture conditions were evaluated. Bone differentiation-related gene expression (aged and young RAOBs in OD+ or OD- groups; n = 8, respectively) was analyzed by quantitative polymerase chain reaction.
resultsTransplantation of RAOBs encapsulated in GelMA-RF into palatal or femoral defects resulted in significantly earlier bone-like tissue formation compared with controls. RAOBs showed sufficient mineralization in a 3D-culture environment. Bone differentiation-related gene expression was significantly increased in 3D cultures.
conclusionsTaken together, GelMA-RF, particularly when combined with RAOBs, provides a supportive scaffold for bone differentiation and may represent a novel bone-regeneration therapy for complex/extensive bone defects, even when combined with immature alveolar-bone osteoblasts from aged rats. PLAIN LANGUAGE SUMMARY: Regenerative medicine combining scaffold materials and cell transplantation shows promise for widespread bone regeneration. This study focused on gelatin methacryloyl (GelMA) as a scaffold material. We developed GelMA (GelMA-RF) that gelated under visible light, avoiding the disadvantage of UV irradiation in conventional methods, and used it as a scaffold for cell transplantation. Furthermore, considering the increasing need for regenerative medicine in elderly patients, this study focused on using immature-osteoblasts derived from aged individuals as transplant cells to verify the bone regenerative capacity. In this study, immature-osteoblasts isolated from the alveolar bone of aged rats were encapsulated in GelMA-RF and transplanted into bone defects, confirming early bone regeneration sufficiently. Furthermore, in vitro analysis confirmed bone formation-related gene expression and calcification capacity, demonstrating that GelMA-RF is a suitable material for bone regeneration. These findings suggest that even alveolar bone immature-osteoblasts derived from aged individuals, when combined with GelMA-RF, hold promise as a novel therapeutic approach for regenerating complex and extensive bone defects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.